Patients receiving murine monoclonal antibody therapy for malignancy develop T cells that proliferate in vitro in response to these antibodies as antigens.

por Kosmas, C., Epenetos, A. A., Courtenay-Luck, N. S.
Publicado 1991

Characterisation and internalisation of recombinant humanised HMFG-1 antibodies against MUC1

por Pericleous, L M, Richards, J, Epenetos, A A, Courtenay-Luck, N, Deonarain, M P
Publicado 2005

Antibody-guided irradiation of malignant pleural and pericardial effusions.

por Pectasides, D., Stewart, S., Courtenay-Luck, N., Rampling, R., Munro, A. J., Krausz, T., Dhokia, B., Snook, D., Hooker, G., Durbin, H.
Publicado 1986

Impact of antibody framework residue V(H)-71 on the stability of a humanised anti-MUC1 scFv and derived immunoenzyme

por Krauss, J, Arndt, M A E, Zhu, Z, Newton, D L, Vu, B K, Choudhry, V, Darbha, R, Ji, X, Courtenay-Luck, N S, Deonarain, M P, Richards, J, Rybak, S M
Publicado 2004